Currently no disease-modifying or neuroprotective treatments exist for MSA, nor are there effective medications to treat the cerebellar ataxia in MSA-C or the parkinsonian features in MSA-P. Physical ...
Emrusolmin is expected to improve symptoms of MSA by targeting alpha synuclein oligomers. The Food and Drug Administration (FDA) has granted Fast Track designation to emrusolmin (TEV-56286) for the ...
Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy ...
MELBOURNE, Australia and SAN FRANCISCO, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing ...
Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension –– New analysis increases overall confidence in the ...
At least, that is what doctors thought the first day he was in the hospital in late June.
NEW YORK, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its ...
"Multiple System Atrophy Clinical Trials Analysis"DelveInsight's,“Multiple System Atrophy- Pipeline Insight, 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in ...
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH), today announced completion of enrollment in the open-label portion of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback